The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 06, 2023

Filed:

Jun. 29, 2020
Applicant:

Northwestern University, Evanston, IL (US);

Inventors:

Marco Martina, Evanston, IL (US);

Herbert Y. Meltzer, Evanston, IL (US);

Assignee:

NORTHWESTERN UNIVERSITY, Evanston, IL (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/196 (2006.01); A61K 31/4365 (2006.01); A61P 25/18 (2006.01); A61P 25/24 (2006.01); A61K 31/57 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/196 (2013.01); A61K 31/4365 (2013.01); A61K 31/57 (2013.01); A61P 25/18 (2018.01); A61P 25/24 (2018.01); A61K 45/06 (2013.01);
Abstract

Disclosed are methods for treating a psychiatric disease or disorder and/or symptoms thereof in a subject in need thereof, the method comprising administering to the subject an effective amount of an antagonist of the Na+-K+-2Cl— cation-chloride cotransporter isoform 1 (NKCC1) for treating the psychiatric disorder and/or the symptoms thereof in the subject. The methods further may include administering to the subject a dopamine D1 agonist and/or a GABAagonist, optionally at a subeffective dose, where co-administering the antagonist of NKCC1 improves the efficacy of the dopamine D1 agonist and/or the GABAagonist, optionally at the subeffective dose, for treating the psychiatric disease or disorder and/or symptoms thereof.


Find Patent Forward Citations

Loading…